NASDAQ:ALXO ALX Oncology (ALXO) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free ALXO Stock Alerts $15.02 +0.79 (+5.55%) (As of 12:28 PM ET) Add Compare Share Share Today's Range$14.12▼$15.0350-Day Range$10.72▼$16.7952-Week Range$3.94▼$17.42Volume125,433 shsAverage Volume429,087 shsMarket Capitalization$751 millionP/E RatioN/ADividend YieldN/APrice Target$18.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get ALX Oncology alerts: Email Address ALX Oncology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside31.0% Upside$18.83 Price TargetShort InterestBearish11.47% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.60Based on 12 Articles This WeekInsider TradingSelling Shares$933,000 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.33) to ($2.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.74 out of 5 starsMedical Sector404th out of 910 stocksPharmaceutical Preparations Industry180th out of 426 stocks 3.4 Analyst's Opinion Consensus RatingALX Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageALX Oncology has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.47% of the float of ALX Oncology has been sold short.Short Interest Ratio / Days to CoverALX Oncology has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in ALX Oncology has recently increased by 7.22%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldALX Oncology does not currently pay a dividend.Dividend GrowthALX Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALXO. Previous Next 2.6 News and Social Media Coverage News SentimentALX Oncology has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for ALX Oncology this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for ALXO on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ALX Oncology insiders have sold 1,774.85% more of their company's stock than they have bought. Specifically, they have bought $49,764.00 in company stock and sold $933,000.00 in company stock.Percentage Held by Insiders50.30% of the stock of ALX Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.97% of the stock of ALX Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ALX Oncology are expected to grow in the coming year, from ($3.33) to ($2.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ALX Oncology is -3.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ALX Oncology is -3.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioALX Oncology has a P/B Ratio of 3.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About ALX Oncology Stock (NASDAQ:ALXO)ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.Read More ALXO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALXO Stock News HeadlinesApril 19, 2024 | insidertrades.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Sells $710,000.00 in StockApril 6, 2024 | insidertrades.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Jaume Pons Sells 20,000 SharesApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 20, 2024 | investing.comAlx Oncology's president & CSO sells $710k in stockApril 20, 2024 | americanbankingnews.comJaume Pons Sells 50,000 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) StockApril 18, 2024 | seekingalpha.comALX Oncology: Trying To Justify The HypeApril 18, 2024 | seekingalpha.comENPH, OCUL and ITCI are among after hour moversApril 17, 2024 | americanbankingnews.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest UpdateApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 17, 2024 | americanbankingnews.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of "Moderate Buy" from AnalystsApril 14, 2024 | americanbankingnews.comALX Oncology (NASDAQ:ALXO) Rating Reiterated by Cantor FitzgeraldApril 13, 2024 | uk.investing.comALX Oncology hold rating reiterated with steady stock target by StifelApril 11, 2024 | markets.businessinsider.comBuy Rating on ALX Oncology Holdings Amid Strong Clinical Data and Favorable rNPV AnalysisApril 9, 2024 | globenewswire.comALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)April 8, 2024 | markets.businessinsider.comBuy Rating Justified by Promising Evorpacept Trial Results and Market PotentialApril 6, 2024 | finance.yahoo.comALX Oncology Holdings Inc (ALXO) Insider Sells SharesMarch 20, 2024 | investing.comAlx Oncology CEO buys $49.7k in company sharesMarch 17, 2024 | finance.yahoo.comALXO Apr 2024 7.000 putMarch 16, 2024 | finance.yahoo.comALXO Apr 2024 14.000 putMarch 16, 2024 | finance.yahoo.comALXO Apr 2024 19.000 callMarch 8, 2024 | markets.businessinsider.comALX Oncology’s Evorpacept Shows Promising Potential in Cancer Treatment StudiesMarch 8, 2024 | markets.businessinsider.comALX Oncology Has 'Elevated Valuation' - Analyst Downgrades Stock, Highlights Need For Development De-Risking Beyond Gastric CancerMarch 8, 2024 | realmoney.thestreet.comALX Oncology just downgraded at Stifel, here's whyMarch 8, 2024 | finance.yahoo.comALX Oncology Holdings Inc (ALXO) Reports Growth Amidst Increased R&D SpendingMarch 8, 2024 | investorplace.comALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q4 2023March 7, 2024 | globenewswire.comALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 5, 2024 | globenewswire.comALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual MeetingSee More Headlines Receive ALXO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ALX Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today4/23/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALXO CUSIPN/A CIK1810182 Webwww.alxoncology.com Phone650-466-7125FaxN/AEmployees72Year FoundedN/APrice Target and Rating Average Stock Price Target$18.83 High Stock Price Target$27.00 Low Stock Price Target$11.00 Potential Upside/Downside+25.4%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-160,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-76.10% Return on Assets-62.59% Debt Debt-to-Equity Ratio0.05 Current Ratio5.24 Quick Ratio5.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.81 per share Price / Book3.94Miscellaneous Outstanding Shares50,000,000Free Float24,850,000Market Cap$751 million OptionableOptionable Beta1.58 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Corey S. Goodman Ph.D. (Age 72)Executive Chairman Comp: $84kMr. Jason W. Lettmann (Age 47)CEO & Director Comp: $60.5kDr. Jaume Pons Ph.D. (Age 57)Founder, President, Director & Chief Scientific Officer Comp: $856.29kMr. Peter S. Garcia M.B.A. (Age 62)Chief Financial Officer Comp: $631.11kDr. Sophia Randolph M.D. (Age 56)Ph.D., Chief Medical Officer & Director Comp: $637.24kDr. Michael Chang Ph.D.Vice President of OperationsMs. Shelly Pinto (Age 47)Senior VP of Finance & Chief Accounting Officer Comp: $508.26kDr. Christopher Byrd J.D.Ph.D., General CounselDr. Athanasios Tsiatis M.D.Senior Vice President of Clinical DevelopmentDr. Lin Yeong-Liang M.D.M.S., Senior Vice President of Drug Safety & PharmacovigilanceMore ExecutivesKey CompetitorsAurinia PharmaceuticalsNASDAQ:AUPHDisc MedicineNASDAQ:IRONNurix TherapeuticsNASDAQ:NRIXSavaraNASDAQ:SVRAPraxis Precision MedicinesNASDAQ:PRAXView All CompetitorsInsiders & InstitutionsJaume PonsSold 50,000 sharesTotal: $710,000.00 ($14.20/share)Los Angeles Capital Management LLCSold 24,460 shares on 4/5/2024Ownership: 0.197%Jaume PonsSold 20,000 sharesTotal: $223,000.00 ($11.15/share)Jason LettmannBought 4,400 shares on 3/14/2024Total: $49,764.00 ($11.31/share)Vestal Point Capital LPBought 1,655,000 shares on 2/14/2024Ownership: 3.322%View All Insider TransactionsView All Institutional Transactions ALXO Stock Analysis - Frequently Asked Questions Should I buy or sell ALX Oncology stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ALX Oncology in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALXO shares. View ALXO analyst ratings or view top-rated stocks. What is ALX Oncology's stock price target for 2024? 7 brokers have issued 12 month target prices for ALX Oncology's stock. Their ALXO share price targets range from $11.00 to $27.00. On average, they predict the company's stock price to reach $18.83 in the next year. This suggests a possible upside of 31.0% from the stock's current price. View analysts price targets for ALXO or view top-rated stocks among Wall Street analysts. How have ALXO shares performed in 2024? ALX Oncology's stock was trading at $14.89 at the beginning of the year. Since then, ALXO stock has decreased by 3.4% and is now trading at $14.38. View the best growth stocks for 2024 here. Are investors shorting ALX Oncology? ALX Oncology saw a increase in short interest in March. As of March 31st, there was short interest totaling 3,120,000 shares, an increase of 7.2% from the March 15th total of 2,910,000 shares. Based on an average daily volume of 389,200 shares, the days-to-cover ratio is presently 8.0 days. Approximately 11.5% of the shares of the company are short sold. View ALX Oncology's Short Interest. When is ALX Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ALXO earnings forecast. How were ALX Oncology's earnings last quarter? ALX Oncology Holdings Inc. (NASDAQ:ALXO) announced its quarterly earnings data on Thursday, March, 7th. The company reported ($0.93) EPS for the quarter, missing analysts' consensus estimates of ($0.84) by $0.09. What ETF holds ALX Oncology's stock? Inspire Small/Mid Cap ETF holds 33,156 shares of ALXO stock, representing 0.23% of its portfolio. What other stocks do shareholders of ALX Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other ALX Oncology investors own include Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Innovative Industrial Properties (IIPR), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV) and When did ALX Oncology IPO? ALX Oncology (ALXO) raised $128 million in an initial public offering on Friday, July 17th 2020. The company issued 8,000,000 shares at $15.00-$17.00 per share. Jefferies, Credit Suisse, Piper Sandler and Cantor served as the underwriters for the IPO and LifeSci Capital was co-manager. Who are ALX Oncology's major shareholders? ALX Oncology's stock is owned by a variety of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.20%). Insiders that own company stock include Jason Lettmann, Jaume Pons, Lsv Associates, Llc, Peter S Garcia, Peter S Garcia, Shelly Pinto and Sophia Randolph. View institutional ownership trends. How do I buy shares of ALX Oncology? Shares of ALXO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALXO) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
